Target intelligence / Profile preview

T-cell surface glycoprotein CD3 delta and epsilon chains (CD3δε) (CD3δε)

Target
CD3δε
Molecular classification
Receptor, T-cell receptor complex, Immunoglobulin superfamily, Single-pass type I membrane protein
01

Overview

The CD3δε (CD3 delta-epsilon) heterodimer is a crucial component of the T-cell receptor (TCR) complex, playing a fundamental role in signal transduction following antigen recognition (UniProt P04234, P07766). It consists of two invariant polypeptide chains, delta (δ) and epsilon (ε), which associate with the TCR alpha/beta or gamma/delta chains to facilitate T-cell activation and development (NCBI Gene 915, 916). In therapeutic contexts, CD3δε is a primary target for bispecific antibodies (e.g., BiTEs) designed to redirect T-cells to eliminate malignant cells by cross-linking the TCR with tumor-associated antigens (PubMed: 32661138). While highly effective in treating various hematologic malignancies, targeting this complex can lead to systemic immune activation, resulting in safety concerns such as cytokine release syndrome (CRS) and neurotoxicity (StatPearls: NBK545235). Additionally, monoclonal antibodies against CD3 have been utilized for immunosuppression in organ transplantation and autoimmune disorders by modulating or depleting T-cell populations (DrugBank: DB00075).

Other names
CD3 delta/epsilon complexCD3d/CD3eT3D/T3ET-cell receptor-CD3 complexCD3 complex delta and epsilon subunits
02

Mechanism of action

T-cell redirection and activation via bispecific antigen binding; Immunosuppression via TCR modulation or T-cell depletion

03

Biological functions

Signal transductionImmune responseT-cell activationT-cell differentiationAntigen recognition
04

Disease associations

CancerAutoimmune diseaseGraft-versus-host diseaseType 1 diabetesOrgan transplant rejectionT-cell immunodeficiency
05

Safety considerations

Cytokine Release Syndrome (CRS)Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)LymphopeniaOn-target off-tumor toxicityHypogammaglobulinemia
06

Interacting drugs

Blinatumomab

9 more in the full profile.

07

Biomarkers

CD3+ T-cell countSerum Interleukin-6 (IL-6) levelsSerum FerritinC-reactive protein (CRP)CD25 expressionCD69 expression

Beyond the preview

Go deeper on T-cell surface glycoprotein CD3 delta and epsilon chains (CD3δε) (CD3δε).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on T-cell surface glycoprotein CD3 delta and epsilon chains (CD3δε) (CD3δε).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call